Marks a major milestone in expanding access to this next-generation intravascular imaging technology, helping physicians make more informed decisions across a wide range of coronary interventions ...

Biohaven Ltd. today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small ...

AWS Senior Product Manager Nitin Garg on transitioning technical expertise from regulated healthcare systems to cloud ...

While the AI boom has made robots significantly more capable, the accompanying safety infrastructure has struggled to keep pace. Traditional 2D laser scanners, which are widely used to define safety ...

G.T. School is the gifted-and-talented branch of the same network, just a few miles north of Austin's city limits. Pamela ...

Doceree has been named a Sample Vendor in the Trusted Conversational AI in Life Sciences profile ahead of the July 14 launch ...

What specifically will this look like? Amodei predicts that, over the next five to ten years, AI will achieve, among other ...

EU AI Act Article 50 compliance becomes enforceable on August 2, 2026, requiring chatbot disclosures, deepfake labels, and AI ...

Celltrion used the world's largest biotech exhibition — the 2026 BIO International Convention (Bio USA) in San Diego — to ...

Dynamic Solution is joining forces with Vibatrobotics, a KAIST startup, to strengthen its technological competitiveness in ...

From your perspective, how is the market evolving today, and which elements of Korean technology and treatment philosophy are ...

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “2026 is an inflection year for BeOne’s solid tumor portfolio, marked by the encouraging data we are presenting at ...